Дизайн, синтез и изучение связи структуры и анксиолитической активности N-ацилдипептидных аналогов холецистокинина-4

Список литературы

1. Ivy А.С., Oldberg Е. A gormone mechanism for gollbladder contraction and evacuation. / Am. J. Physiol., 1928, V.86, p.599−613
2. Vanderhaeghen J.J., Signeau J.C., Gepts W. New peptide acting in the vertebrate CNS with anti-gastrin antibodies. / Nature, 1975, V.257, p.604−605
3. Mutt V., Jorpes J.E. Structure of porcine cholecystokinin-pancreozymin. / Eur. J. Biochem., 1968, V.6, p. 156−162
4. Soil A., Amirian D.A., Park J., Elashoff J.D., Yamada T. Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture. / Am. J. Phusiol., 1985, У.248, p. G569-G573
5. Pelto-Hiikko M., Persson H., Schalling M., Hokfelt T. Immunohistochemical demonstration of cholecystokinin-like immunoreactivity in spermatozoa in epididymis. / Acta Phisiol. Scand., 1989, V.137, p.465−466
6. Persson H., Ericsson A., Schalling M., Rehfeld J.F., Hokfelt T. Detection of cholecystokinin in spermatogenic cells. / Acta Phisiol. Scand., 1988, V.134, p.565−566
7. Skirboll L., Hokfelt Т., Rehfeld J., Cuello A.C., Dockray G. Coexistence of substance P- and cholecystokinin-like immunoreactivity in neurons of the mesencephalic periaqueductal central gray. / Neyrosci. Lett., 1982, V.28, p.35−39
8. Gall C., Lauterborn J., Burks., Seroogy K. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. / Brain Res., 1987, V.403, p.403−408
9. Mezey E., Reisine T.D., Skirboll L., Beinfeld M., Kiss J.Z., Cholecystokinin in the medial parvocellular subdivision of the paraventricular nucleus. Coexistence with corticotrophin-releasing hormone. / Ann. NY Acad. Sci., 1985, V.448, p. 152−156
10. Vanderhaeghen J.J., Lotstra F., De May J., Gilles C. Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat. / Proc. Natl. Acad. Sci. USA, 1980, V.77, p. l 190−1194
11. Hays S.E., Beinfeld M.C., Jensen R.T., Goodwin F.K., Paul S.M. Demonstration of a putative receptor site for cholecystokinin in rat brain. / Neutopeptides, 1980, V. l, p.53−62
12. Innis R.B., Synder S.H., Cholecystokinin reseptor binding in brain and pancreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides. / Eur. J. Pharmacol., 1980, V.65, p.123−124
13. Jensen R.T., Lemp G.F., Gardner G.D. Interaction of cholecystokinin with specific membrane receptors on pancreatic acinar cells. / Proc. Natl. Acad. Sci., 1980, V.77, p.2079−2083
14. Saito A., Sankaran H., Goldfine I.D., Williams J.A. Cholecystokinin receptors in the brain: characterization and distribution. / Science, 1980, V.208, p. 1155−1156
15. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M., Roques B.P. International union of pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. / Pharmacological reviews, 1999, V.51, № 4, p.745−781
16. Rosezweig S.A., Miller L.j., Jamieson J.D. Identification and localization of cholecystokinin-binding sites on rat pancreatic plasma membranes and acinar cells: A biochemical and autoradiographic study. / J. Cell Biol., 1983, V.96, p.1288−1297
17. Baldwin G.S., Chandler R., Scanlon D.B., Weinstock J. Identification of a gastrin binding protein in porcine gastric mucosal membranes by covalent crosslinking with iodinated gastrin-2−17. / J. Biol. Chem., 1986, V.261, p.12 252−12 257
18. Menozzi D., Gardner J.D., Maton P.N. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. / 1989, V.257, p. G73-G79
19. Wank S.A. Cholecystokinin receptors. / Am. J. Physiol., 1995, V.269, p. G628-G646.
20. Vanhoutte P.M., Humprey P.P.A., Spedding M. XI. International union of pharmacology. Recommendations for nomenclature of new receptor subtypes. / Pharmacol. Rev., 1996, V.48, p. 1−2
21. Davison J.S., Najafl-Farashah A. Dibutyryl cyclic GMP, a competitive inhibitor of choleystokinin/pancreizymin and related peptides in the gallbladder and ileum. / Can. J. Physiol. Pharmacol., 1981, V.59, p. l 100−1104
22. Baldwin G.S. Gastrin receptor structure, in Gastrin (Walsh J.H. ed.) / Raven Press, New York, 1993, p. 195−207
23. Ovchinikov Y.A., Ablulajew N.G., Bogachuck A.S. Two adjacent cysteine residues in the C-terminal cytoplasmatic fragment of bovine rhodopsin are palmitoylated. / FEBS Lett., 1988, V.230, p. 1−5
24. Dohlman H.G., Thorner J., Caron M.G., Lefkowitz R.J. Model systems for the study of seven-transmembrane-segment receptors. / Annu. Rev. Biochem., 1991, V.60, p.653−680
25. Wank S.A., Pisegna J.R., de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. / Proc. Natl. Acad. Sci. USA, 1992, V.89, p.8691−8695
26. Kopin A.S., Lee Y.M., McBride E.W., Miller L.J., Lu M., Lin H.Y., Kolakowski L.F., Beinborn M. Expression, cloning and characterization of the canine parietal cell gastrin racaptor. / Proc. Natl. Acad. Sci. USA, 1992, V.89, p.3605−3609
27. Berridge M.J. and Irvine R.F. Inositol phosphates and cell signaling. / Nature (Lond.), 1989, V.341, p. 197−205
28. DelValle J.Y., Tsunoda Y., Williams J.A., Yamada T. Regulation of Ca2+.- by secretagogue stimulation of canine gastric parietal cells. / Am. J. Phisiol., 1992, V.262, G420-G426
29. Lignon M.F., Bernard N., Martinez J. Cholecystokinin increases intracellular Ca2+ concentration in the human JARKAT T lymphocyte cell line. / Eur. J. Pharmacol., 1993, V.245, p.241−246
30. Yoshida H., Tsunoda Y., Owyang C. Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. / Am. J. Physiol., 1997, V.273, G735-G747
31. Akagi K., Nagao T., Urushidani T. Calcium oscillations in single cultured Chinese Hamster Ovary cells stably transfected with cloned human cholecystokinin (CCK)b receptor. / Jpn. J. Pharmacol., 1997, V.75,p.33−42
32. Pommier B., Da Nascimento S., Dumon S., Bellier B., Million E., Garbay C., Roques B.P., Noble F. The CCK-B receptor is coupled to two effector pathways through pertussis sensitive and insensitive G proteins. / J. Neurochem.
33. Talkad V.D., Fortune K.P., Polio D.A., Shah G.N., Wank S.A., Gardner J.D. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. / Proc. Natl. Acad. Sci. U.S.A., 1994, V.91, p.1868−1872
34. Huang S.C., Fortune K.P., Wank S.A., Kopin A.S., Gardner J.D. Multiple affinity states of different cholecystokinin receptors. / J. Biol. Chem., 1994, V.269, p.26 121−26 126
35. Durieux C., Coppey M., Zajac J.M., Roques B.P. Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. / Biochem. Biophys. Res. Commun., 1986, V.137, p. 1167−1173
36. Rodriguez M., Lignon M.F., Galas M.C., Amblard M., Martinez J. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors. / Mol. Pharmac., 1990, V.38, p.333−341
37. Harper E.A., Roberts S.P., Shankley N.P., Black J.W. Analysis of variation in L-365,260 competition cyrves in radioligand binding assays. / Br. J. Pharmac., 1996, V. l 18, p.1717−1726
38. Kenakin T. Agonist-receptor efficacy. II: Agonist trafficking of receptor signals. / Trends Pharmacol. Sci., 1995, V. l6, p.232−238
39. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. / Nature (Lond.), 1993, V.365, p. 170−174
40. Anders J., Bluggel M., Meyer H.E., Kuhne R., ter Laak A.M., Kojro E., Fahrenholz F. Direct identification of the agonist binding site in the human brait cholecystokinin B receptor. / Biochemistry, 1999, V.38, p.6043−6055
41. Jagerschmidt A., Guillaume-Rousselet N., Vikland M.L., Goudreau N., Maigret B., Roques B.P. IIis381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity. / Eur. J. Pharmacol., 1996, V.296, p.97−106
42. Knight M., Tamminga C.A., Steardo L., Beck M.E., Barone P., Chase T.N. Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin reseptors. / Eur. J. Pharmacol., 1997, V.105, p.49−55
43. Miyasaka K., Funakoshi A., Jimi A., Nakamura R., Matsumoto M., Kitani K. Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats. / Dig. Dis. Sci., 1992, V.32, p.369−377
44. Xiao-Dong H., Nelson M.T., Mulvihill S.J., Bunnett N.W., Debas H.T. Critical role of intrapancreatic cholecystokinin in mediating the pancreatic response to vagal stimulation. / Gastroenterology, 1993, V.104, p. A344
45. Gibbs J., Young RS, Smith G.P. Cholecystokinin decreases food intake in rats. / Am. J. Psychol., 1973, V.84, p.488−495
46. Smith G.P., Gibbs J. The development and proof of the CCK hypothesis of satiety, in Multiple Cholecystokinin Receptors in the CNS (Dourish C.T., Cooper S J., Iversen S.D., Iversen L.L. eds.) / Oxford University Press, p. 166−182
47. Crawley J.N., Corwin R.L. Biological action of cholecystokinin. / Peptides, 1994, V.15, p.731−755
48. Geary N., Kissileff H.R., Pi-Sunyer F.X., Hinton V. Individual, but not simultaneous, glucagons and cholecystokinin infusions inhibit feeding in men. / Am. J. Physiol., 1992, V.262, p. R975-R980
49. Melton P.M., KissilefF H.R., Pi-Sunyer F.X. Cholecystokinin (CCK-8) affects gastric pressure and ratings of hunger and fullness in women. / Am J. Physiol., 1992, V.263, p. R452-R456
50. Gourch A., Orosco M., Rodrigues M., Martinez J., Cohen Y., Jacquot C. Effects of a new cholecystokinin analogue (JMV 236) on food intake and brain monoamines in the rat. / Neuropeptides, 1990, V.15,p.37−41
51. Kaneyuki T., Morimasa T., Shohomori T. Action on peripherally administered cholecystokinin on monoaminergic and GABAergic neurons in the rat brain. / Acta Med. Okayama, 1989, V.43, p.153−159
52. Orosco M., Duche J.C., Rybarczyk M.C., Rouch C., Cohen Y., Jacquot C. Variability of changes in obese rat brain monoamines in response to cholecystokinin. / Gen. Pharmacol., 1986, V.17, p.665−669
53. Cooper S.J., Dourish C.T. Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding. / Physiol. Behav., 1990, V.48, p.849−857
54. Crawley J.N., Fiske S.M., Durieux C., Derrien., Roques B.P. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. / J. Pharmacol. Exp. Ther., 1991, V.257, p.1076−1080
55. Dourish C.T., Ruckert A.C., Tattersall F., Iverson S.D. Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors. / Eur. J. Pharmacol., 1989, V.173, p.233−234
56. Smith G.P., Tyrka A., Gibbs J. Type-A CCK receptors mediate the inhibition of food intake and activity by CCK-8 in 9-to 12-day old rat pups. / Pharmacol. Biochem. Behav., 1991, V.38, p.207−210
57. Miesner J., Smith G.P., Gibbs J., Tyrka A. Intravenous infusion of CCK-A receptor antagonist increases food intake in rats. / Am. J. Physiol., 1992, V.262, p. R216-R219
58. Moran T.H., Ameglio P.J., Peyton H.J., Schwartz G.J., McHugh P.R. Blockade of type A, but not type B, CCK receptors, postpones satiety in rhesus monkeys. / Am. J. Physiol., 1993, V.265, p. R620-R624
59. Reidelberger R.D., O’Rourke M.F. Potent cholecystokinin antagonist L-354,718 stimulates food intake in rats. / Am. J. Physiol., 1989, V.257, p. R1512-R1518
60. Harty R.F., Pearson P.H., Solomon T.E., McGuigan J.E. Cholecystokinin, vaoactive intestinal peptide and peptidehistidine methionine responsese to feeding in anorexia nervosa. / Regul. Pept., 1991, V.36, p.141−150
61. Tamai H., Takemura J., Kobayashi N., Matsubayashi S., Matsukara S., Nakagawa T. Changes in plasma cholecystokinin concentration after oral glucose tolerance test in anorexia nervosa before and after therapy. / Metabolism, 1993, V.42, p.581−584
62. Geracioto T.D., Liddle R.A. Impaired cholecystokinin secretion in bulimia nervosa. / N. Engl. J. Med., 1988, V.319, p.683−688
63. Sandvik A.K., Waldum H.L. CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. / Am. J. Physiol., 1991, V.260, p. G925-G928
64. Dourish C.T., Rycroft W., Iverson S. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors. / Science, 1989, V.245, p.1509−1511
65. Corrwin R.L., Gibbs J., Smith G.P. Increased food intake after type A but not type B cholecystokinin receptor blockade. / Physiol. Behav., 1991, V.50, p.255−258
66. Moran T.H., Ameglio P.J., Schwartz G.J., McHugh P.R. Blickade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. / Am. J. Physiol., 1992, V.262, p. R46-R50
67. Reidelberger R.D., Varga G., Solomon T.E. Effects of selective cholecystokinin antagonist L-364,718 and L-365,260 on food intake in rats. / Peptides, 1991 V.12, p.1215−1221
68. Palacios J.M., Savasta M., Mengod G. Does cholecystokinin colocalize with dopamine in the human substantia nigra? / Brain Res., 1989, V.488, p.369−375
69. Shalling M., Friberg K., Seroogy K. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. / Proc. Natl. Acad. Sci. USA, 1990, V.87, p.8427−8431
70. Chang R.S.L., Lotti V.S., Martin G.E., Chen T.B. Increase in brain 125L-cholecystokinin (CCK) recepror binding following chronic haloperidol treatment, itracisternal 6-hydroxydopamine and ventral tegmental lesions. / Life Sci., 1983, V.32, p.871−878
71. Suzuki T., Moroji T., Hori T., Bada A., Kawai N., Koizumi J. Autoradiographic localization of CCK-8 binding sites in the brain: effects of chronic metamphetamine on these sites. / Biol. Psichiatry, 1993, V.34, p.781−790
72. Dumbrille-Ross A., Seeman P. Dopamine receptor elevation by cholecystokinin. / Peptides, 1984, V.5, p.1207−1212
73. Hommer D.W., Skirboll L.R. Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons. / Eur. J. Pharmacol., 1983, V.91, p.151−152
74. Crawley J.N., Hays S.E., Paul S.M., Goodwin F.K. Cholecystokinin reduces exploratory behavior in mice. / Physiol. Behav., 1981, V.27, p.407−411
75. Kadar T., Borda L., Penke B., Kovacs K., Telegdy G. Cataleptogenic and anticataleptic activity produced by cholecystokinin octapeptides in mice. / Neuropeptides, 1985, V.6, p.259−268
76. Crawley J.N. Cholecystokinin-dopamine interactions. / Trends Pharmacol. Sci., 1991, V.12, P.232−236
77. Hommer D.W., Stoner G., Crawley J.N., Paul S.M., Skirboll L.R. Cholecystokinin-dopamune coexistence: electrophysiological actions corresponding to cholecystokinin receptor subtype. / J. Neurosci., 1986, V.6, p.3039−3043
78. Scirboll L.R., Grace A.A., Hommer D.W. Peptide monoamine coexistence: Studies of actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. / Neuroscience, 1981, V.6, p.2111−2124
79. Kelland M.D., Zhang J., Chiodo L.A., Freeman A.S. Receptor selectivity of cholecystokinin effects of mesoaccumbens dopamine neurons. / Synapse, 1991, V.8, p.137−143
80. Rasmussen K., Czachura J.F., Stockton M.E., Howbert J.J. Electrophysiological effects of diphenylpyrazolidinone on cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. / J. Pharmacol. Exp. Ther., 1993, V.264, p.480−488
81. Rasmussen K., Stockton M.E., Czachura J.F., Howbert J.J. Cholecystokinin (CCK) and schizophrenia: The selective CCK-B antagonist LY262691 decreases midbrain dopamine unit activity. / Eur. J. Pharmacol., 1991, V.209, p.135−138
82. Chiodo L.A., Bunney B.S. Population response of midbrain dopaminergic neurons to neurileptics: Further studies on time course and nondopaminergic neuronal influences. / J. Neurosci., 1987, V.7, p.629−633
83. Vaccarino F.J., Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. / Behav. Neurosci., 1989, V.103, p.831−6
84. Crawley J.N., Stivers J.A., Blumstein L.K., Paul S.M. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence. / J. Neurosc., 1985, V.5, p.1972−1983
85. Crawley J.N. Subtype-selective cholecystokinin receptor antagonists block cholecustokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. / J. Neurosci., 1992, V.12, p.3380−3391
86. Crawley J.N., Stivers J. A., Hommer D.W., Skirboll L.R., Paul S.M. Antagonists of central and peripheral behavioral actions of cholecystokinin. / J. Pharmacol. Exp. Ther., 1986, V.236, p.320−330
87. Dauge V., Bohme G.A., Crawley J.N. Investigation of behavioral and electrophysiological responsese induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog: BC 264. / Synapse, 1990, V.6, p.73−80
88. Vigro L., Humphries C., Mortimer A., Barnes T., Hirsch S., de Belleroehe J. Choleeystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. / Biol. Psichiatry, 1995, V.37, p.694−701
89. Bachus S.E., Hyle T.M., Herman M.M., Egan M.F., Kleinman J.E. Abnormal cholecystokinin mRNA levels in entorhinalcortex of schizophrenia. / J. Psychiatr. Res., 1997, V.31, p.233−256
90. Farmery S.M., Owen F., Poulter M., Crow T.J. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic pacients. / Life Sci., 1985, V.36, p.473−477
91. Ferrier I.N., Roberts G.W., Crow T.J. Reduced high affinity cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. / Life Sci., 1983, V.33, p.475−482
92. Studler J.M., Javoy-Agid F., Ceccelin F., Legrand J.C., Agid Y. CCK-8 immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients. / Brain. Res., 1982, V.243, p.176−179
93. Hays S.E., Goodwin F.K., Paul S.M. Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of Huntington’s disease. / Brain Res., 1981, V.225, p.452−456
94. Hays S.E., Houston S.H., Beinfeld M.C., Paul S.M. Postnatal ontogeny of cholecystokinin receptors in rat brain. / Brain Res., 1981, V.213, p.237−241
95. Zetler G. Caerulein and its analogues, neurophaxmacological properties. / Peptide, 1985, V.6(suupl.), p.33 046
96. Van Ree J.M., Gaffori O., De Wild D. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic drugs. / Eur. J. Pharmacol., 1983, V.93, p.63−78
97. Lang A., Harro J., Soosaar A. Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. / Naunyn-Schmiedeberg's Arch Pharmacol., 1995, V.351, p.363−370
98. Wettstein J.G., Grouhel A., Earley B., Junien J.L. Unique behavioral profiles of CCK antagonists in rats. / Soc. Neurosci. Abstr., 1992, V.18, p.815
99. Csernansky J.G., Glick S., Mellentin J. Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function. / Psychopharmacology, 1987, V.91, p.440−444
100. Innis R.B., Bunney B.S., Charney D.S. Does the cholecystokinin antagonist proglumide possess antipsychotic activity. / Psychiat. Res., 1986, V.18, p. 1−7
101. Hicks P.B., Vinogradov S., Riney S.J., Su K., Csernansky J.G. A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenia. / J. Clin. Psychopharmacol., 1989, V.9, p.200−212
102. Lotstra F., Verbanck P.M.P., Mendelewicz J., Vanderhaegen J.J. No evidence of antipsychotic effects of caerulein in scizothrenic patients free of neuroleptics: a double-bind crossover study. / Biol. Psychiatry, 1984, v. 19, p.877−882
103. Tamminga C.A., Littman R.L., Alphs L.D., Chase T.N., Thaker G.K., Wagman A.M. Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. / Psychopharmacology, 1986, V.8, p.387−391
104. Gall C., Lauterborn J., Burks D., Seroogy K. Co-localozation of enkephalins and cholecystokinin in discrete areas of rat brain. / Brain. Res., 1987, V.403, p.403−408
105. Faris P.L., McLaughlin C.L., Baile C.A., Olney J.W., Komisaruk B.R. Morthine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin./ Science, 1984, V.226, p.1215−1217
106. Baber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulein, and CCK antagonists in nociception. / Pain, 1989, V.39, p.307−328
107. Faris P.L., Komisaruk B.R., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. / Science, 1983, V.219, p.310−312
108. Roques B.P., Noble F., Dauge V., Fornie-Zalusci M.C., Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. / Pharmacol. Rev., 1993, V.45, p.87−146
109. Noble F., Derrien M., Roques B.P. Modulation of opioid analgesia by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. / Br. J. Pharmacol., 1993, V.109, 1064−1070
110. Noble F., Roques B.P. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. / Progress in Neurobiology, 1999, V.58, p.349−379
111. Valverde O., Madonado R., Fornie-Zalusci M.C., Roques B.P. Cholecystokinin B antagonist strongly potentiate antinociception mediated by endogenous enkephalins. / J. Pharmacol. Exp. Ther., 1994, V.270, p.77−88
112. Lavigne G.j., Millington W.R., Mueller G.P. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in nonacclimated rats exposed to a novel environment. / Neuropeptides, 1992, V.21, p. 119−129
113. O’Neill M.F., Dourish C.T., Tye S.J., Iversen S.D. Blockade of cCK-B receptors by L-365,260 induces analgesia in the squirrel monkey. / Brain. Res., 1990, V.534, p.287−290
114. Roques B.P., Noble F. Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction. / Neurochem. Res., 1996, V.21, p.1395−1409
115. Willner P. Animal models of depression: an overview. / Pharmacol. Ther., 1990, V.45, p.425−455
116. Derrien M., Durieux M., Roques B.P. Antidepressant-like effects in mice: antagonism by natrindole. / Br. J. Pharmacol., 1994, V. lll, p.956−960
117. Hernando F., Fuentes J.A., Roques B.P., Ruiz-Gayo M. The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type in the forced-swim test in mice. / Eur. J. Pharmacol., 1994, V.261, p.257−263
118. Dauge V., Roques B.P. Opioid and CCK systems in anxiety and reward, in Cholecystokinin and Anxiety: From Neuron to Behavior (Bradwejn J. and Vasar E. eds.) / RG Landes Company, Austin, p.151−171
119. Hernando F., Fuentes J.A., Fornie-Zalusci M.C., Roques B.P., Ruiz-Gayo M. Antidepressant-like affects of CCK-B receptor antagonists: involvement of the opioid system. / Er. J. Pharmacol., 1996, V.318, p.221−229
120. Smadja C., Maldonado R., Turcaud S., Fornie-Zalusci M.C., Roques B.P. Oposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like essects. / Psychopharmacology, 1995, V.120, p.400−408
121. Crawley J.N., Vanderhaeghen J.-J. Neuronal cholecystokinin. / 1985, Ann. NY Acad. Sei., V.448, p. 1−697
122. Rehfeld J.F. CCK and anxiety: Introduction. In: Multiple cholecystokinin receptors in the CNS (Dourish C.T., Coopr S.J., Iversen S.D., Iversen L.L. eds.). / Oxford: Oxford University Press, 1992
123. Harro J., Vasar E. Evidence that CCK-B receptors mediate the regulation of exploratory behaviour in the rat. / Eur. J. Pharmacol., 1991, V.193, p.379−381
124. Palmour R.M., Ervin F.R., Bradwejn J., Howbert J.J. Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCK-B antagonist LY2626991. / Soc. Neurosci. Abstr., 1991, V.17, p.637−641
125. Boden P.R., Higginbottom M., Hill D.R. Cholecystokinin dipeptoid antagonists: Design, Synthesis, and anxiolytic properties of some novel CCK-A and CCK-B selective and «mixed» CCK-A/CCK-B antagonists. / J. Med. Chem., 1993, V.36, p.552−565
126. Chopin P., Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus maze. / Psychopharmacology (Berlin), 1993, V.110, p.409−414
127. Costall B., Domeney A.M., Hughes J., Kelly M.E., Naylor R.J., Woodruff G.N. Anxiolytic effects of CCK-B antagonists. / Neuropeptides, 1991, V. 19 (suppl.), p.65−73
128. Hughes J., Boden P., Costall B. Development of a class of selective cholecystokinin type B receptor antagonists having poternt anxiolytic activity. / PNAS USA, 1990, V.87, p.6728−6732
129. Powell K.R., Barrett J.E. Evaluation of the effects of PD 134 308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. / Neuropeptides, 1991, V.19 (suppl.), p.75−78
130. Rataud J., Darche F., Piot O., Stutzmann J.M., Bohme G.a., Blanchard J.-C. «Anxiolytic» effect of CCK-antagonists on plus-maze behavior in mice. / Brain Res., 1991, V.548, p.315−317
131. Singh L., Field M.J., Hughes J. The behavioral properties of CI-988, a selective cholecystokinin-B receptor antagonist. / Br. J. Pharmacol., 1991, V.104, p.239−245
132. Dauge V., Roques B.P. Opioid and CCK systems in anxiety and reward, in Cholecystokinin and Anxiety: From Neuron to Behavior (Bradwejn J. and Vasar E. eds.) / RG Landes Company, Austin, p. 151−171
133. Hernando F., Fuentes J.A., Fornie-Zalusci M.C., Roques B.P., Ruiz-Gayo M. Antidepressant-like affects of CCK-B receptor antagonists: involvement of the opioid system. / Er. J. Pharmacol., 1996, V.318, p.221−229
134. Smadja C., Maldonado R., Turcaud S., Fornie-Zalusci M.C., Roques B.P. Oposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like essects. / Psychopharmacology, 1995, V.120, p.400−408
135. Crawley J.N., Vanderhaeghen J.-J. Neuronal cholecystokinin. / 1985, Ann. NY Acad. Sci., V.448, p. 1−697
136. Rehfeld J.F. CCK and anxiety: Introduction. In: Multiple cholecystokinin receptors in the CNS (Dourish C.T., Coopr S.J., Iversen S.D., Iversen L.L. eds.). / Oxford: Oxford University Press, 1992
137. Harro J., Vasar E. Evidence that CCK-B receptors mediate the regulation of exploratory behaviour in the rat. / Eur. J. Pharmacol., 1991, V.193, p.379−381
138. Palmour R.M., Ervin F.R., Bradwejn J., Howbert J.J. Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCK-B antagonist LY2626991. / Soc. Neurosci. Abstr., 1991, V.17, p.637−641
139. Boden P.R., Higginbottom M., Hill D.R. Cholecystokinin dipeptoid antagonists: Design, Synthesis, and anxiolytic properties of some novel CCK-A and CCK-B selective and «mixed» CCK-A/CCK-B antagonists. / J. Med. Chem., 1993, V.36, p.552−565
140. Chopin P., Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus maze. / Psychopharmacology (Berlin), 1993, V.110, p.409−414
141. Costall B., Domeney A.M., Hughes J., Kelly M.E., Naylor R.J., Woodruff G.N. Anxiolytic effects of CCK-B antagonists. / Neuropeptides, 1991, V. 19 (suppl.), p.65−73
142. Hughes J., Boden P., Costall B. Development of a class of selective cholecystokinin type B receptor antagonists having poternt anxiolytic activity. / PNAS USA, 1990, V.87, p.6728−6732
143. Powell K.R., Barrett J.E. Evaluation of the effects of PD 134 308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. / Neuropeptides, 1991, V.19 (suppl.), p.75−78
144. Rataud J., Darche F., Piot O., Stutzmann J.M., Bohme G.a., Blanchard J.-C. «Anxiolytic» effect of CCK-antagonists on plus-maze behavior in mice. / Brain Res., 1991, V.548, p.315−317
145. Singh L., Field M.J., Hughes J. The behavioral properties of CI-988, a selective cholecystokinin-B receptor antagonist. / Br. J. Pharmacol., 1991, V.104, p.239−245
146. Vasar E., Harro J., Lang A., Pold A., Soosaar A. Differential involvement of cCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. / Psychopharmacology (Berlin), 1991, V.105, p.393−399
147. Harro J., Vasar E. Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour?/Neurosci. Biobehav. Rev., 1991, V.15, p.473−477
148. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. / Trends Pharmacol. Sci., 1993, V.14, p.244−249
149. Dooley D.J., Klamt I. Differential profile of the CCK-B receptor antagonist CI-988 and diazepam in the 4-plate test. / Psychopharmacology, 1993- V. l 12, p.452−454
150. Harro J., Kiivet R.A., Lang A., Vasar E. Rats with anxious or non-anxious type of exploratory behaviour differ in their CCK-8 and benzodiazepine receptor characteristics. / Behav. Brain Res., 1990, V.39, p.63−71
151. Palmour R.M., Brawejn J., Ervin F.R. The anxiogenic effects of CCK-4 in monkeys are reduced by CCK-B antagonists, benzodiazepines or adenosine A2 agonists. / Eur. Neuropsychopharmacol., 1992, V.2, p. 193−195
152. Проскурякова T.B., Беспалова Ж. Д., Палькеева М. Е., Петриченко О. Б., Панкратова Н. В., Шохонова В. А., Анохина И. П. Биологическая активность аналогов холецистокинин-(ЗО-ЗЗ)-тетрапептида. / Боорганическая химия, 2005, Т.31, № 2, с. 130−139
153. Анохина И.П., Проскурякова Т. В., Панкратова Н. В., Петриченко О. Б., Беспалова Ж. Д., Палькеева М. Е., Юсупов Д. В. Тетрапептид Trp-Nle-Asp-PheNH-CH(CH3)2, обладающий анксиолитической активностью. / Патента РФ №RU2142813/C1, 1999, Бюл. № 35
154. Vanderhaegen J.j., Lotstra F., Demey J., Gilles C. Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rats. / PNAS USA, 1980, V.77, p. l 190−1194
155. Wise R.A., Rompre P.P. Brain dopamine and reward. / Annual. Rev. Psychol., 1989, V.40, p. 191−225
156. Derrien M., Durieux M., Dauge V., Roques B.P. Involvement of D2 dopaminergic receptors in the emotional and motivational responses induced by injection of cCK-8 in the posterior part of the rat nucleus accumbens. / Brain Res., 1993, V.617, p.181−188
157. Crawley J.N. Interactions between cholecystokinin and other neurotransmitter systems. / In: Cholecystokinin and Anxiety: From Neuron to Behavior (Bradwejn J., Vassar E. eds.), RG Landes Company, Austin / 1995, p.35−56
158. De Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. / Arch. Gen. Psychiatry, 1989, V.46, p.511−517
159. Abelson J.L., Nesse R.M. Cholecystokinin-4 and panic. / Arch. Gen. Psychiatry, 1990, V.47, p.67
160. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. / Arch. Gen. Psychiatry, 1991, V.48, p.603−610
161. De Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. / Arch. Gen. Psychiatry, 1989, V.46 p.511−517
162. Bradwejn J., Koszycki D., Annable L., du Tertre A.C., Reines S., Karakanias C. A doseranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. / Biol. Psychiatry, 1992, V.32, p.903−912
163. Bradwejn J., Koszycki D. Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients. / Am. J. Psychiatry, 1994, V.151, p.261−263
164. Bradwejn J., Koszycki D., du Tertre A.C., Paradis M., Bourin M. The effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. / Psychopharmacology (Berlin), 1994
165. Lydiard R.B., Ballenger J.C., Laraia M.T., Fossey M.D., Beinfeld M.C. CSF cholecystokinin concentrations in patients with panic disorders and in normal comparison subjects. / Am J. Psychiatry, 1992, V.149, p.691−693
166. Brambilla F., Bellodi L., Perna G., Garberi A., Sacerdote P. Lymphocyte cholecystokinin concentration in panic disorder. / Am. J. Psychiatry, 1993, V.150, p. 1111−1113
167. Bradwejn J. Cholecystokinin and panic disorder. / In: Cholecystokinin and Anxiety: From Neuron to Behavior (Bradwejn J., Vassar E. eds.), RG Landes Company, Austin / 1995, p.73−86
168. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. / Biol. Psychiatry., 1995, V.38, № 11, p.742−746
169. Kramer M.S., Culter N.R., Ballenger J.C. A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. / Biol. Psychiatry, 1995, V.37, p.462−466
170. Pande A.C., Greiner M., Adams J.B., Lydiard R.B., Pierce M.W. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. / Biol. Psychiatry., 1999, V.46, № 6, p.860−862
171. Bradwejn J., Koszycki D., Payeur R., Bourin M., Borthwick H. Replication of action of cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings. / Am. J. Psychiatry, 1992, V.149, p.962−964
172. Harro J., Oreland L. Cholecystokinin receptors and memory: A radial maze study. / Pharmacol. Biochem. Behav., 1993, V.44, p.509−517
173. Itoh S., Takashima A., Igano K., Inouye K. Memory effect of caerulein and its analoges in active and passive avoidance responses in the rat. / Peptides, 1989, V.10, p.843−848
174. Itoh S., Takashima A., Maeda Y. Memory impairments induced by peripherally administered cholecystokinin A-type receptor antagonists in rats. / Drag. Dev. Res., 1992, V.26, p.89−99
175. Katsuura G., Itoh S. Passive avoidance deficit following intracerebroventricular administration of cholecystokinin terapeptide amide in rats. / Peptides, 1986, V.7, p.809−814
176. Lemaire M., Piot O., Roques B.P., Bonme A.G., Blanchard J.C. Evidence for an endogenous cholecystokininergic balance in social memory. / NeuroReport, 1992, V.3, p.925−932
177. Lemaire M., Barneoud P., Bonme A.G., Piot O., Haun F., Roques B.P., Blanchard J.C. CCK-A and CCK-B receptors enhance olfactory recognition via distinct neutonal pathways. / Psychopharmacology, 1994, V.115, p.435−440
178. Derrien M., Dauge V., Blommaert A., Roques B.P. The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. / Behav. Brain Res., 1994, V.65, p.139−146
179. Derrien M., McCort-Trannchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. /Pharmacol. Biochem. Behav., 1994, V.49, p.133−141
180. Million M.E., Lena I., Da Nascimento S., Noble F., Dauge V., Garbay C., Roques B.P. Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCK-B receptor. / Lett. Peptide Sci., 1997, V.4, p.407−410
181. Chang R.S.L., Lotty V.G., Monogghan R.L., Birnbaum J., Hensens O.D., Springer J.P. A potent nonpeptide cholecystokinin antagonist selective for- peripheral tissues isolated from Aspergillus alliaceus. / Sciance (Wash D.C.), 1985, V.230, p.177−179
182. Evans B.E., Rittel K.E., Bock M.G., DiPardo R.M., Freidinger R.M., Whitter W.L. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists. / J. Med. Chem., 1987, V.30, p. 1229−1239
183. Pierson M.E., Comstock J.M., Simmons R.D., Kaiser F., Julien R., Zongrone J., Rosamond J.D. Synthesis and biological evalution of potent, selective, hexapeptide CCK-A agonist anorectic agents. / J. Med. Chem., 1997, V.40, p.4302−4307
184. Henke B.R., Aquino C.J., Birkemo L.S., Croom D.K., Yingling J., Willson T.M. Optimization of 3-(lH-indazol-3-ylmethyl)-l, 5-benzodiazepines as potent, orally active CCK-A agonists. / J. Med. Chem., 1997, V.40, p.2706−2725
185. Macovec F., Chiste R., Bani M., Revel L., Setnikar I., Rovati L.A. New glutamic and aspartic derivatives with potent CCK-antagonistic activity. / Eur. J. Med. Chem., 1986, V.21, p.9−20
186. Rovati A.L., Casula P.L., Da Re G. Pharmacological and experimental toxicology of a new nonanticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamde-Milid). / Minerva Med., 1967, V.58, p.3656−3670
187. Hull R.A., Shankley N.P., Harper E.A., Gerkowitch V.P., Black J.W. 2-Naphthalenesulphonyl-L-aspartyl-(2-phenyl)amide (2-NAP) a selective cholecystokinin CCKA-receptor antagonist. / Br. J. Pharmacol., 1993, V.108, p.734−740
188. Evans B.E., Bock M.G., Rittle K.E., DiPardo R.M., Whitter W.L., Veber D.R., Anderson P. S., Freidinger R.M. Designe of potent, orally effective, nonpeptidel antagonists of the peptide hormone cholecystokinin. / PNAS USA, 1986, V.83, p.4918−4922
189. Gully D., Frehel D., Marcy C., Spinazze A., Kespy L., Neliat G., Maffrand J.P., Le Fur G. Peripheral biological activity of SR 27 897: A new potent non-peptide antagonist of CCK-A receptors. / Eur. J. Pharmacol, 1993, V.232, p.13−19
190. Akiyama T., Tachibana I., Hirohata Y., Shirohara H., Yamamoto M., Otsuki M. Pharamacological profile of TP-680, a new cholecystokinin-A receptor antagonist. / Br. J. Pharmacol., 1996, V.117, p. 1558−1564
191. Taniguchi H., Yazaki N., Yomota E., Shikano T., Endo T., Nagasaki M. Pharmacological profile of T-0632, a novel potent and selective CCK-A receptor antagonist, in vivo. / Eur. J. Pharmacol., 1996, V.312, p.227−233
192. Charpenter B., Dor A., Roy P., England P., Pham H., Durieux C., Roques B.P. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. / J. Med. Chem., 1989, V.31, p. l 184−1190
193. Charpenter B., Durieux C., Pelaprat D., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Enzyme-resistant CCK analogs with high affinities for central receptors. / Peptides, 1988, V.9, p.835−841
194. Bock M.G., DiPardo R.M., Evans B.E., Rittle K.E., Whitter W.L. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. / J. Med. Chem., 1989, V.32, № 1, p.13−16
195. Lotti V.J., Chang R.S. A new potent and selective nonpeptide gastrin antagonist and brain cholecystokinin receptor (CCKB) ligand: L-365,260. / Eur. J. Pharmacol., 1989, V.162, p.273−280
196. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvment of the brain cholecystokinin B receptor in anxiety. / Proc. Natl. Acad. Sci. U.S.A., 1991, V.88, p. l 1 301 133
197. Chopin P., Briley M. The benzodiazepine antagonist flumazenil blocks the CCK reseptor agonists and antagonists in the elevated plus-maze. / Psychopharmacology (Berl), 1993, V. l 10, № 4, p.409−414
198. Lin J.H., Storey D.E., Chen I.W., Xu X. Improved oral absorption of L-365, 260, a poorly soluble drag. / Biopharm drag dispos., 1996, V.17, № 1, p.1−15
199. Chambers M.S., Hobbs S.C., Fletcher S.R. L-708,474: the C5-ciclogexyl analogue of L-365,260, f selective, high-affinity ligand for the CCK-B/gastrin reseptor. / Bioorg. Med. Chem. Lett. 1993, V.3, p.1919−1924
200. Showell G.A., Bourrain S., Neduvelil J.G., Fletcher S.R. High-affinity and potent water-soluble 5-amino-l, 4benzodiazepine CCKB/gastrin reseptor antagonists containing a cationic solubilizing group. / J. Med. Chem., 1994, V.37, № 6, p.719−721
201. Bock M.G., DiPardo R.M., Evans B.E., Mellin E.C., Newton R.C. Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. / J. Med. Chem., 1994, V.37, № 6, p.722−724
202. Bohme G.A., Bertrand P., Guyon C., Capet M., Pendley C., Stutzmann J.M., Martin G., Blanchard J.C. The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. / Ann. NY Acad. Sci., 1994, V.713, p. l 18−120
203. Bertrand P., Bohme G.A., Durieux C., Guyon C., Capet M., Pendley C., Martin G. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. / Eur. J. Pharmacol., 1994, V.262, p.233−245
204. Pendley C., Fitzpatrick L.R., Capolino A.J., Davis M.A., Bertrand P., Guyon C., Martin G. RP 73 870, a gastrin/cholecystokinin receptor antagonist with potent antiulser activity in the rat. / J. Pharmacol. Exp. Ther., 1995, V.273, p.1015−1022
205. McDonald I.M. CCK2receptor antagonists. / Exp. Opin. Ther. Patents., 2001, V. l 1, p.445−462
206. Reggiani A., Gerrard P.A., Maraia G., Melotto S., Ratti E., Gaviraghi G., Trist D.G. Anxiolytic activity of GV150013, a new potent and selective cholecystokinin-B (CCK-B) antagonist. / Br. J. Pharmacol., 1995, V. l 14(Proceedings Suppl), p.92P
207. Chambers M.S., Fletcher S.R. CCK-B antagonists in the control of anxiety and gastric acid secretion. In: Progress in Medicinal Chemistry (King F.D., Oxford A.W. ed.). / 2000, V.37. Oxford: Elsevier Science, p.45−81
208. Lowe J.A., Hageman D.L., Drozda A.E., McLean S., Bryce D.K., Crawfold R.T., Zorn S., Morrone J., Bordner J. 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. / J. Med. Chem., 1994, V.37, p.3789−3811
209. Lowe J.A., Drozda A.E., McLean S., Bryce D.K., Crawfold R.T. A water soluble benzazepine cholecystokinin-B recptor antagonist. / Bioorg. Med. Chem. Lett., 1995, V.5, p.1933−1936
210. Yu M.J., Thrasher K.J., McCowan J.R., Mason N.R., Mendelsohn L.G. Quinazolinone Cholecystokinin-B receptor ligands. / J. Med. Chem., 1991, V.34, № 4 p. 1505−1508
211. Yu M.J., McCowan J.R., Mason N.R., Deeter J.B., Mendelsohn L.G. Synthesis and X-ray crystallographic analysis of quinazolinone cholecystokinin/gastrin reseptor ligands. / J. Med. Chem., 1992, V.35, № 14, p.2534−2542
212. Howbert J.J. Lob K.L., Britton T.C., Mason N.R., Bruns R.F. Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry. / Bioorg. Med. Chem. Lett., 1993, V.5, p.875−880
213. Padia J.K., Chilvers H., Daum P., Pinnock R., Suman-Chauhan N., Webdale L., Trivedi B.K. Design and synthesis of novel nonpeptide CCK-B receptor antagonists. / Bioorg. Med. Chem. Lett., 1997, V.7., p.805−810
214. Low C.M.R., Black J.W., Broughton H.B. Development of peptide 3D structure mimetics: rational design of novel peptoid cholecistokinin receptor antagonists. / J. Med. Chem., 2000, V.43, p.3505−3517
215. Horwell D.C. Development of CCK-B antagonists. / Neuropeptides, 1991, V. 19 (Suppl.), p.57−64
216. Martinez j., Rodrigues M., Bali J.-P., Laur J. Phenylethylamide derivatives of the C-terminal tetrapeptide of gastrin. / Int. J. Pept. Protein Res., 1986, V.28, p.529−535
217. Kalindjian S.B., Buck I.M., Davies J.M.R., Dunstone D.G., Hudson M.L., Low C.M., McDonald I.M., Pether M.J., Steel K.I., Tozer M.J., Vinter J.G. Non-peptide cholecistokinin
218. B/gastrin receptor antagonists based on bicyclic, heteriaromatic sceletons. / J. Med. Chem., 1996, V.39, p.1806−1815
219. Horwell D.C., Brchmore B., Boden P.R., Higginbottom M. a-Methyl tryptophanylphenylalanines and their arylethylamine «dipeptoid» analogues. of the tetraprptide cholecystokinin (30−33). / Eur. J. Med. Chem., 1990, V.25, p.53−60
220. Kearney A.S., Mehta S.C., Radebaugh G.W. Aqueous stability and solubility of CI-988, a novel «dipeptoid» cholecystokinin-B receptor antagonist. / Pharm. Res., 1992, V.9, № 8, p. 10 921 095.
221. Feng R., Hinton J.P., Hoffman K., Parker T.D., Wright D.S. Pharmacokinetics and oral bioavailability of the anxiolytic CI-988 ester prodrugs in wistar rats. / Pharm. Res., 1993, V.10, № 10, p. S-346
222. Hinton J.P., Rutkowski K., Johnson E.L., Wright D.S. Single dose pharmacokinetics and absolute bioavailability of the anxiolytic CI-988 in fasted and fed cynomolgus monkeys.. / Pharm. Res., 1991, V.8, № 10, p. S-267
223. Hinton J.P., Hoffman G., Poisson A., Klemisch W., Wright D.S. Mass balance and disposition of 14C. CI-988 in cynomolgus monkeys. / Pharm. Res., 1993, V.10, № 10, p. S-330
224. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J.P., Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. / Biol. Psychiatry., 1995, V.38, p.742−746
225. Macovec F., Peris W., Revel L., Giovanetti R., Mennuni L., Rovati L.C. Structure-antigastrine activity relationships of new ®-4-benzamido-5-oxopentanoic acid derivatives. / J. Med. Chem., 1992, V.35, p.28−38
226. Revel L., Ferrari F., Macovec F., Rovati L.C., Impicciatore M. Characterization of antigastrin activity in vivo of CR 2194 a new R-4-benzamido-5-oxo-pentanoic acid derivative. / Eur J. Pharmacol., 1992, V.216, p.217−224
227. Macovec F., Peris W., Frigerio S., Giovanetti R., Letari O., Mennuni L., Revel L. Structure-antigastrine activity relationships of new spiroglumide amido acid derivatives. / J. Med. Chem., 1996, V.39, p.135−142
228. Macovec F.D., D’Amato M. cckb/gastrin receptor antagonists as potential drugs for peptic ulcer therapy. / Dug. Discov. Today, 1997, V.2, p.283−293
229. Macovec F., Revel L., Letari O., Mennuni L., Impicciatore M. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCKe antagonist. / Eur. J. Pharmacol., 1999, V.369, p.81−90
230. Revel L., Mennuni L., Garofalo P., Macovec F. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity. / Behav. Pharmacol., 1998, V.9, № 3, p. l83−194
231. Murphy M.G., Sytnic B., Kovacs T.O., Mertz H., Ewanic D., Shingo S., Lin J.H., Gertz B.J., Walsh J.H. The gastrin-receptor antagonist L-365,260 ingibits stimulated acid secretion in humans. / Clin. Pharmacol. Ther., 1993, V.54, p.533−539
232. Westenberg H.G.M., Van Megen H.J.G.M., Den Boer J.A. Effects of the cholecystokinin-B antagonist L-365,260 on lactate-induced panic disorder (PD) patients. / Psychopharmacol. Bull., 1994, V.30, p.644
233. Chen I.W., Dorley J.M., Ramjit H.G., Pitzenberger S.M., Lin J.H. Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals./ Drag. Metab. Dispos., 1992, V.20, p.390−395
234. Lin J.H., Storey D.E., Chen I.W., Xu X. Impruved oral absorption of L-365,260, a poorly soluble drag. / Biopharm. Drag. Dispos, 1996, V.17, p.1−15
235. Herranz R. Cholecystoknin antagonists: Pharmacological and therapeutic potential. / Med. Research Rev., 2003, V.23, p.559−605
236. Singh L" Field M.J., Hughes J., Menzies R., Oles R.J., Vass C.A., Woodruff G.N. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. / Br. J. Pharmacol., 1991, V.104, № 1, p.239−245
237. Macovec F., Peris W., Frigerio S., Giovanetti R., Letari O., Mennuni L., Revel L. Structure-antigastrine activity relationships of new spiroglumide amido acid derivatives. / J. Med. Chem., 1996, V.39, p.135−142
238. Macovec F.D., D’Amato M. CCKs/gastrin receptor antagonists as potential drugs for peptic ulcer therapy. / Dug. Discov. Today, 1997, V.2, p.283−293
239. Macovec F., Revel L., Letari O., Mennuni L., Impicciatore M. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCKs antagonist. / Eur. J. Pharmacol., 1999, V.369, p.81−90
240. Revel L., Mennuni L., Garofalo P., Macovec F. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity. / Behav. Pharmacol., 1998, V.9, № 3, p. 183−194
241. Murphy M.G., Sytnic B., Kovacs T.O., Mertz H., Ewanic D., Shingo S., Lin J.H., Gertz B.J., Walsh J.H. The gastrin-receptor antagonist L-365,260 ingibits stimulated acid secretion in humans. / Clin. Pharmacol. Ther., 1993, V.54, p.533−539
242. Westenberg H.G.M., Van Megen H.J.G.M., Den Boer J.A. Effects of the cholecystokinin-B antagonist L-365,260 on lactate-induced panic disorder (PD) patients. / Psychopharmacol. Bull., 1994, V.30, p.644
243. Chen I.W., Dorley J.M., Ramjit H.G., Pitzenberger S.M., Lin J.H. Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals./ Drag. Metab. Dispos., 1992, V.20, p.390−395
244. Lin J.H., Storey D.E., Chen I.W., Xu X. Impruved oral absorption of L-365,260, a poorly soluble drag. / Biopharm. Drag. Dispos, 1996, V.17, p. 1−15
245. Herranz R. Cholecystoknin antagonists: Pharmacological and therapeutic potential. / Med. Research Rev., 2003, V.23, p.559−605
246. Singh L., Field M.J., Hughes J., Menzies R., Oles R.J., Vass C.A., Woodruff G.N. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. / Br. J. Pharmacol., 1991, V.104, № 1, p.239−245
247. Rasmussen K., Yu M.J., Czachura J.F. Quinazolinone cholecystokinin (CCK)-B antagonists decrease midbrain dopamine unit activity. / Synapse, 1994, V.17, № 4, p.278−282
248. Helton D.R., Berger J.E., Czachura J.F., Rasmussen K., Kallman MJ. Central nervous system characterization of the new cholecystokininB antagonist LY 288 513. Pharmacol. Biochem. Behav., 1996, V.53, p.493−502
249. Izumi T., Inoue T., Tsuchiya K., Hashimoto S., Ohmori T., Koyama T. Effect of the CCKB receptor antagonist LY288513 on conditioned fear strees in rats. / Eur. J. Pharmacol., 1996, V.300, p.25−31
250. Rasmussen K., Czachura J.F., Kallman M.J., Helton D.R. The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle. /Neuroreport., 1996, V.7, p.1050−1052
251. Rasmussen K., Helton D.R., Berger J.E., Scearce E. The CCK-B antagonist LY288513 blocks diazepam-withdrawalOinduced increases in auditory startle response. / Ann. NY Acad. Sci., 1994, V.713, p.374−376
252. Crespi F. Cholecystokinin-B (CCK-B) receptor antagonists improve «aged» slep: A new class of sleep modulators? / Methods Find Exp. Clin. Pharmacol., 1999, V.21, p.31−38
253. Yano K., Kajyama A., Yamazaki S., Matsumura Y., Watanabe K., Yamamoto K. In vitro stability and in vivo absorpyion studies of colloidal particles formed from a solid dispersion system. / Chem. Pharm. Bull. (Tokyo), 1996, V.44, p.2309−2313
254. Revel L., Ferrari F., Makovec F., Rovati L.C., Impicciatore M. Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. / Eur. J. Pharmacol., 1992, V.216, p.217−224
255. Beltinger J., Hidelbrand P., Drewe J., Christ A., Hlobil K., Ritz M., D’Amato M., Rovati L., Belinger C. Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. / Eur. J. Clin. Invest., 1999, V.29, p. 153−159
256. Revel L., Mennuni L., Garafolo P., Makovec F. CR 2945: A novel CCKb receptor antagonist with anxiolytoc-like activity. / Behav. Pharmacol., 1998, V.9, p. 183−194
257. Fontana M.G., Donato F., Villanacci., Ghirardi M., Moneghini D., Di Betta E., Salerni B. Inhibitory effect of a gastrin receptor antagonist, CR 2945, on 1,2-dimethylhydrazine-induced colorectal cabcer in mice. / Eur. Surg. Res., 1999, V.31, p.406−411
258. Hasenohrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K., Huston J.P. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. / Neuropeptides., 2000, V.34, № 5, p.272−280
259. Czeh В., Fuchs E., Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. / Expert. Opin. Investig. Drugs., 2006, V.15, № 5, p.479−486
260. Holmes A., Picciotto M.R. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? / CNS Neurol. Disord. Drug. Targets, 2006, V.5, № 2 p.225−232
261. Reinscheid R.K., Xu Y.L. Neuropeptide S and its receptor: a newly deorphanized G proteincoupled receptor system. / Neuroscientist, 2005, V. l 1, № 6, p.532−538
262. Reinscheid R.K., Xu Y.L., Civelli O. Neuropeptide s: a new player in the modulation of arousal and anxiety. / Mol. Interv., 2005, V.5, № 1, p.42−46
263. Wettstein J.G., Earley В., Junien J.L. Central nervous system pharmacology of neuropeptide Y. / Pharmacol. Ther., 1995, V.65, № 3, p.397−414
264. Munglani R., Hudspith M.J., Hunt S.P. The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. / Drugs, 1996, V.52, № 3, p.371−389
265. Balasubramaniam A. Clinical potentials of neuropeptide Y family of hormones. / Am. J. Surg., 2002, V. l83, № 4, p.430−434
266. Shemyakin M.M., Ovchinnikov Y.A., Ivanov V.T. Topochemical investigations of peptide systems. / Angew. Chem. Int. Ed. Engl., 1969, V.8, p.492−499
267. Овчинников Ю.А. Биоорганическая химия / Издательство «Просвещение», Москва, 1987, с.173−175
268. Chorev М., Goodman М. A dozen years of retro-inverso peptidimimetics. / Acc. Chem. Res., 1993, V.26, p.266−273
269. Chorev M., Goodman M. Recent developments in retro peptides and proteins an ongoing topochemical exploration. / Trends Biotechol., 1995, V.13, № 10, p.438−445
270. Гудашева Т.А., Островская Р. У., Трофимов C.C., Косой М. Ю., Иенкина Ф. В., Буров Ю. В., Сколдинов А. П. Пептидные аналоги пирацетама как лиганды предполагаемых ноотропных рецепторов. / Хим.-Фарм. Журн., 1985, Т.19, № 11, с.1322−1324
271. Гудашева Т.А., Зайцева Н. И. Конструирование потенциального дипептидного нейролептика Дилепта. / Хим.-Фарм. Журн., 2005, Т.39, № 5, с.6−11
272. Chorev М. The partial retro-inverso modification: a road traveled together. / Biopolymers, 2005, V. 80, p. 67−84
273. Dooley C.T., Chung N.N., Wilkes B.C., Schiller P.W., Bidlack J.M., Pasternak G.W., Houghten R.A. An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. / Science, 1994, V.266, № 5193, p.2019−2022
274. Srinivasan M., Gienapp I.E., Stuckman S.S., Rogers C.J., Jewell S.D., Kaumaya P.T., Whitaere C.C. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. / J. Immunol., 2002, V.169, № 4, p.2180−2188
275. Snyder E.L., Meade B.R., Saenz C.C., Dowdy S.F. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. / PLoS Biol., 2004, V.2, № 2, р. ЕЗб
276. Bonny C., Oberson A., Negri S., Sauser C., Schorderet D.F. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. / Diabetes, 2001, V.50, № 1, p.77−82
277. Cohen N. Claude (Edited by) / Guidebook on molecular modeling in drug design. / Academic Press, 1995, p.69, p.241
278. Cohen N. Claude (Edited by) / Guidebook on molecular modeling in drug design. / Academic Press, 1995, p.69,81−82
279. Fersht A.R. Basis of biological specificity. / Trends Biochem, Sci., V.9, p.145−147
280. Miyamoto S., Kollman P.A. Absolute and relative binding free energy calculations of the interaction of biotin and its analogs with streptavidin using molecular dynamics/free energy perturbation approaches. / Proteins, 1993, V.16, № 3, p.226−245
281. Burley S.K., Petsko G.A. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. / Science, 1985, V.229, № 4708, p.23−28
282. Chakrabarti P., Samanta U. CH/pi interaction in the packing of the adenine ring in protein structures. / J. Mol. Biol., 1995, V.251, № 1, p.9−14
283. Levitt M., Perutz M.F. Aromatic rings act as hydrogen bond acceptors. / J. Mol. Biol., 1988, V.201, № 4, p.751−754
284. Препаративная органическая химия. / Издательство «Химия», Москва, 1964, с. 429−430
285. Тэйэр М.А. Синтезы органических препаратов. Т.1 / Издатинлит, 1949, с. 69
286. Гельферих Ф., Шеффер Дж. Синтезы органических препаратов. Т.1 / Издатинлит, 1949, с. 471
287. Титце JT., Айхер Т. Препаративная органическая химия. / Издательство «Мир», Москва, 1999, с. 187−188
288. Гудашева Т.А., Василевич Н. И., Сколдинов А. П. Лабораторная пропись ГВС-111. / Москва, НИИ Фармакологии РАМН, 1997
289. BaumannE. / Вег., 1886, V.19, р.3218
290. Вейганд-Хильгетаг Методы эксперимента в органической химии. / Издательство «Химия», Москва, 1968, с.349−350, 396−397, 433−434
291. Гринштейн Дж., Виниц М. Химия аминокислот и пептидов. / Издательство «Мир», 1965, с. 365, 396−397
292. Brenner М., Huber W. / Helv. Chim. Acta, 1953, V.36-S, p. 1109−1115
293. Guttmann S., Boissonnas R.A. / Helv. Chim. Acta., 1958, V.41, p. 1852−1867
294. Гросс Э., Майенхофер И. / Пептиды. Основные методы образования пептидных связей. / Издательство «Мир», Москва, 1983, с.268−313
295. Corson В.В., Scott R.W., Vose С.Е. / Org. Synth., 1929, V.9, p.36
296. Вейганд-Хильгетаг / Методы эксперимента в органической химии. / Издательство «Химия», Москва, 1968, с.455
297. Pellow S., Chopin P., File S.E., Briley M. Validation of opentclosed arm entries in an elevated plus-maze as a measure of anxiety in the rat. / J. Neurosci. Methods, 1985, V.14, p.149−167
298. Органикум. Практикум по органической химии Т.2 / Издательство «Мир», Москва, 1979, с. 91,104
299. Гершкович А.А., Кибирев В. К. Химический синтез пептидов. / Издательство «Наук, думка», 1992, с.200−201
300. Suzuki К., Sasaki Y. / Chem. Pharm. Bull., 1973, V.21, № 12, p.2634−2638
301. Chou P.Y. and Fasman G.D. Beta-turns in proteins. / J. Mol. Biol., 1977, V. l 15, p.135−175
302. Boussard G., Marraud M., Aubry A. Experimental investigations on the backbone folding of praline-containing model tripeptides. / Biopolymers, 1979, V. l8, p. 1297−1331
303. Burgess A.W., Ponnuswamy P.K., Scheraga H.A. / Isr. J. Chem., 1974, V.12, p.239−286
304. Ball J.B., Hughes R.A., Alewood P.F., Andrews P.R. p-Turn topography. / Tetrahedron, 1993, V.49, № 17, p.3479−3488
305. Rao B.N.N., Kumar A., Balaram H., Ravi A., Balaram P. Nuclear Overhauser effects and circular dihroism as probes of P-turn conformation in acyclic and cyclic peptides with Pro-X sequences. / J. Am. Chem. Soc., 1983, V.105, p.7423 7428
306. Zimmerman SS, Scheraga HA. Influence of local interactions on protein structure. I. Conformational energy studies of N-acetyl-N'-methylamides of Pro-X and X-Pro dipeptides. / Biopolimers, 1977, V.16, p.811−843
307. Зайцева Н.И., Лезина В. П., Игнашин A.H, Брилинг B.K., Гудашева Т. А. Изучение конформационных особенностей биологически активных амидов N-ацилпролилтирозинов с помощью 'Н ЯМР-спектроскопии. / Хим.-фарм. Журн., 2001, Т.35, № 7, с.35−38
308. Boussard G. and Marraud M. p-Turns in model dipeptides. An infrared quantitative analysis withNMR correlation. / J. Am. Chem. Soc., 1985, V.107, p. 1825−1828
309. IUPAC-IUB Commission on Biochemical Nomenclature. Abbreviations and symbols for the description of the conformation of polypeptide chains. Tentative rules (1969). / Biochemistry, 1970, V.9, № 18, p.3471−3479
310. Быстрое В.Ф. Вклад спектроскопии ЯМР в изучение структурно-функциональных соотношений белково-пептидных веществ. / Биоорганическая химия, 1984, Т. 10, № 8, с.997−1043
311. Aubry A., Cung М. Т., Marraud М. pi- and piI-Turn conformations in model dipeptides with the Pro-Xaa sequences. / J. Am. Chem. Soc., 1985, V.107, p.7640 764
312. Chandrasecaran R., Lakshminarayanan A.V., Pandya U.V., Ramachandran G.H. Conformation of the LL and LD hairpin bends with internal hydrogen bonds in protein and peptides. / Biochemica et Biophysica Acta, 1973, V.303, p. 14−27
313. Pietrzynski G., Kubica Z., Rzeszotarska B. Conformational propensities of model peptides with a, p-dehidroamino acids. / Peptides 1990, E. Giralt, D. Andrew (eds.), ESCOM Sci. Pub. В. V., 1991, p.462−464
314. Freidinger R.M., Veber D.F., Perlow D.S., Brooks J.R., Saperstein R. Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog. / Science, 1980, V.210, № 4470, p.656−658
315. Freidinger R.M., Perlow D.S., Veber D.F. Protected lactam-bridged dipeptides for use as conformational constraints in peptides. / J. Org. Chem., 1982, V.47, № 1, p.104−109
316. Gross E., Witkop В. Nonenzymatic cleavage of peptide bonds: the methionine residues in bovine pancreatic ribonuclease. / J. Biol. Chem., 1962, V.237, № 6, p. 1856−1860
317. Rich D.H., Tarn J.P. A convenient synthesis of the amino acid, 1-aminocyclopropane-l-carboxylic acid. / Synthesis, 1978, V. l, p.46
318. Vitoux В., Aubry A., Cung M.T., Boussard G., Marraud M. N-methyl peptides. III. Solution conformational study and crystal structure of N-pivaloyl-L-prolyl-N-methyl-N'-isopropyl-L-alaninamide. / Int. J. Pept. Protein. Res., 1981, V. l7, № 4, p.469−479
319. Curtins Т., Goebel F. / J. Pract. chem., 1888, V.37, p. 150
320. Anderson G.W., Zimmerman J.E., Callahan F.M. Reinvestigation of the mixed carbonic anhydride method of peptide synthesis. / J. Am. Chem. Soc., 1967, V.89, p.5012−5017
321. Rydon H.N., Smith P.W.G. / J. Chem. Soc., 1956, p.3642−3650
322. Bodanszky M" Tolle J.C. / Int. J. Pept. Protein Res., 1977, V.10, p.380−384
323. Stewart F.H.C. / Aust. J. Chem, 1965, V. l8, p.887−901
324. Battersby A.R., Robinson J.C. / J. Chem. Soc., 1955, p.259−269
325. Govardhan Ch.P., Pratt R.F. / Biochemistry, 1987, V.26, № 2, p.3385−3395
326. NaKane M. (Squibb E.R. and Sons, Inc.) // U.S. US 4,735,962 (Cl.514−382- C07D409/06), 1988